INSMED INC Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments
INSMED INC (INSM) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments of $37.85 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-22.
Discontinued › Shareholders' Equity › Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments · last filed 2024-02-22
- INSMED INC adjustments to additional paid in capital, equity component of convertible debt, subsequent adjustments for the quarter ending 2021-12-31 was $0.00.
- INSMED INC adjustments to additional paid in capital, equity component of convertible debt, subsequent adjustments for the quarter ending 2021-09-30 was $0.00.
- INSMED INC adjustments to additional paid in capital, equity component of convertible debt, subsequent adjustments for the quarter ending 2021-06-30 was $37.85M.
- INSMED INC adjustments to additional paid in capital, equity component of convertible debt, subsequent adjustments for fiscal 2021 was $37.85M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments 6 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments 9 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $0.00 derived: sum of 2 quarters · filed 2024-02-22 | $37.85M derived: sum of 3 quarters · filed 2024-02-22 | $37.85M 10-K · filed 2024-02-22 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $37.85M derived: sum of 2 quarters · filed 2022-10-27 | $37.85M 10-Q · filed 2022-10-27 | |
| 2021-06-30 | $37.85M 10-Q · filed 2022-08-04 | $37.85M 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |